Literature DB >> 6716275

Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man.

B Oosterhuis, R J ten Berge, H P Sauerwein, E Endert, P T Schellekens, C J van Boxtel.   

Abstract

The lymphocytopenic effect of prednisolone as quantified by OKT3- and OKT4-positive lymphocyte counts in peripheral blood was studied. Single oral prednisolone doses of 10, 30 and 60 mg, respectively, were given to three groups of five subjects. The time courses of prednisolone concentration and lymphocytopenic effects were related by a pharmacokinetic-pharmacodynamic model. The computer program NONLIN was used for parameter estimation. The pharmacodynamic component of the model was a hyperbolic function in which a threshold concentration parameter had to be incorporated. Apparently, this parameter represents depletion of endogenous hydrocortisone after the administration of prednisolone. The results of this study suggest that the prednisolone-induced lymphocytopenia is not related to mRNA transcription and protein synthesis. Furthermore, prednisolone and hydrocortisone seem to be equipotent in man with respect to the studied effect. Smaller doses of prednisolone are relatively more effective due to saturation of the effect and increasing depletion of endogenous hydrocortisone by higher doses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716275

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.

Authors:  H Derendorf; H Möllmann; M Krieg; S Tunn; C Möllmann; J Barth; H J Röthig
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Role of altered prednisolone-specific lymphocyte sensitivity in chronic renal failure as a pharmacodynamic marker of acute allograft rejection after kidney transplantation.

Authors:  X X Kang; T Hirano; K Oka; E Sakurai; T Tamaki; M Kozaki
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma.

Authors:  R P Koopmans; R E Jonkers; M C Braat; C J van Boxtel
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

5.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

6.  Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose.

Authors:  N A Al Katheeri; I A Wasfi; M Lambert; A Saeed
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 7.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants.

Authors:  Sebastian Oliver Decker; Frieder Keller; Jens Mayer; Sylvia Stracke
Journal:  Med Klin (Munich)       Date:  2009-06-16

9.  Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men.

Authors:  E F L Dubois; M G M Derks; D H Schweitzer; A H Zwinderman; P N R Dekhuijzen; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  2004-05-19       Impact factor: 2.953

10.  A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.

Authors:  T Yamamoto; J Yasuda; M Kanao; H Okada; T Oguma; H Yamada
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.